Multiplexed therapeutic drug monitoring of antipsychotics in dried plasma spots by LC-MS/MS
Ruggiero et al.
The finding, in our words
A multiplex LC-MS/MS method for dried plasma spots was fully validated for accuracy, precision, selectivity and sensitivity across seven antipsychotics, with limits of quantification ranging from 0.12 to 5.70 µg/L; this enables convenient therapeutic drug monitoring from a simple dried sample.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Guidance on capillary-to-plasma conversion: method- and analyte-specific clinical validation with paired capillary–venous samples before reporting plasma-equivalent results.
In lung and renal transplant recipients, VAMS sampling with LC-MS/MS quantification of mycophenolic acid and tacrolimus showed good linearity and accuracy, and with a haematocrit-adjusted conversion formula achieved clinical agreement in most samples; tacrolimus did not require haematocrit correction. The approach is virtually painless and enables richer sampling for more accurate drug exposure estimates, supporting decentralised therapeutic drug monitoring.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
This study found that volumetric absorptive microsampling shows satisfactory agreement with venous plasma for monitoring several antiseizure medications in paediatric patients. However, a blood-to-plasma conversion factor was required to estimate plasma concentrations for clobazam and carbamazepine metabolites due to poor capillary-to-plasma interchangeability.